Genmab A/S (GMAB) Company Overview

Company Announcement COPENHAGEN, Denmark; January 23, 2025 – Genmab A/S (Nasdaq: GMAB) has announced that the Board has approved the distribution of 4,903 restricted stock units and 5,289 warrants to its employees and those of its subsidiaries. Each restricted stock unit is given at no cost and gives the holder a conditional right to obtain one share in Genmab A/S, valued at DKK 1.

On January 22, 2025, Genmab A/S announced that DARZALEX® net sales reached USD 11,670 million in 2024. This figure includes sales from the subcutaneous version, known as DARZALEX FASPRO® in the U.S. The total sales comprised USD 6,588 million from the U.S. and USD 5,082 million from other countries, with Genmab earning royalties from Johnson & Johnson's sales.

Investors looking at stocks in the Medical - Biomedical and Genetics sector may be familiar with Genmab A/S Sponsored ADR (GMAB) and Qiagen (QGEN). However, which of these two stocks is more appealing for value investors?

Genmab (GMAB) could see an increase in its stock price due to rising confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #2 (Buy).

At Zacks, we concentrate on the reliable Zacks Rank system, which highlights earnings estimates and changes in those estimates to identify excellent stocks. At the same time, we keep an eye on the most recent trends in value, growth, and momentum to support our top selections.

Media Release COPENHAGEN, Denmark; January 03, 2025 Genmab A/S (Nasdaq: GMAB) has announced that its CEO, Jan van de Winkel, Ph.D., will give a company update at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for January 14, 2025, at 3:00 PM PST / 6:00 PM EST, which is 12:00 AM CET on January 15, 2025. You can watch the live and recorded webcast on Genmab's website at https://ir.genmab.com/events-presentations.

A virtual media release event will be hosted by Genmab A/S today, December 11, 2024, at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The 2024 R&D Update and ASH Data Review Meeting will be conducted in English and can be accessed through a live webcast. The event will also be available for later viewing on www.genmab.com.

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) has shared new long-term findings from two ongoing clinical trials that are testing epcoritamab, a bispecific antibody that engages T-cells, given as a subcutaneous injection to adult patients with diffuse large B-cell lymphoma (DLBCL). The results come from Arm 1 of the Phase 1b/2 EPCORE® NHL-2 trial (NCT04663347), which is assessing the fixed-duration use of epcoritamab alongside rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) has shared early results from the EPCORE® CLL-1 trial, showing an overall response rate (ORR) of 61 percent and a complete response (CR) rate of 39 percent in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who had already undergone multiple treatments. Among those who responded to the treatment, 75 percent had no detectable minimal residual disease (MRD), meaning they showed no signs of the disease after treatment.